bluebird bio is a biotechnology company focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector gene addition platform. Co. has two gene therapies: ZYNTEGLO® (betibeglogene autotemcel, also known as beti-cel) and SKYSONA® (elivaldogene autotemcel, also known as eli-cel). ZYNTEGLO is for the treatment of adult and pediatric patients with B-thalassemia who require regular red blood cell transfusions. SKYSONA is for slowing the progression of neurologic dysfunction in boys four to 17 years of age with early active cerebral adrenoleukodystrophy. We show 43 historical shares outstanding datapoints in our BLUE shares outstanding history coverage, used to compute BLUE market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BLUE market cap history over the course of time is important for investors
interested in comparing BLUE's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BLUE versus a peer is one thing; comparing
BLUE market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BLUE can fluctuate over the course of history.
With this page we aim to empower investors researching BLUE by allowing them to research the BLUE market cap history. |
Free BLUE Email Alerts:
Video: The Importance of Market Cap
